About HitGen
HitGen is a company based in Lanzhou (China) founded in 2012. It operates as a Professional Services, and SaaS (Software-as-a-Service). HitGen has raised $39.11 million across 2 funding rounds from investors including Gates Foundation, CDH and Shiyu Capital. The company has 483 employees as of December 31, 2024. HitGen has completed 1 acquisition, including Vernalis. HitGen offers products and services including DNA Encoded Library (DEL), Fragment-Based Drug Discovery (FBDD/SBDD), Oligonucleotide-Based Therapeutics (OBT), and Targeted Protein Degradation (TPD). HitGen operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Omniome, among others.
- Headquarter Lanzhou, China
- Employees 483 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Hitgen Inc. Class A
-
Annual Revenue
$58.19 M (USD)15.58as on Dec 31, 2024
-
Net Profit
$7.04 M (USD)26.13as on Dec 31, 2024
-
EBITDA
$15.97 M (USD)94.03as on Dec 31, 2024
-
Total Equity Funding
$39.11 M (USD)
in 2 rounds
-
Latest Funding Round
-
Investors
Gates Foundation
& 2 more
-
Employee Count
483
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of HitGen
HitGen is a publicly listed company on the SSE with ticker symbol 688222 in China, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of HitGen
HitGen offers a comprehensive portfolio of products and services, including DNA Encoded Library (DEL), Fragment-Based Drug Discovery (FBDD/SBDD), Oligonucleotide-Based Therapeutics (OBT), and Targeted Protein Degradation (TPD). The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Technology used for designing and screening compound libraries.
Methods applied for structure-based drug design optimization.
Platform developed for nucleic acid drug discovery.
Technology utilized for protein degradation drug development.
Unlock access to complete
Funding Insights of HitGen
HitGen has successfully raised a total of $39.11M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Last Round
-
First Round
First Round
(28 May 2018)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2018 | Amount | Grant - HitGen | Valuation |
investors |
|
| May, 2018 | Amount | Series B - HitGen | Valuation | CDH , Shiyu |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in HitGen
HitGen has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Gates Foundation, CDH and Shiyu Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and private debt firm focused on multiple sectors
|
Founded Year | Domain | Location | |
|
Shiyu Capital is engaged in equity investment and asset allocation.
|
Founded Year | Domain | Location | |
|
Charitable foundation investments on poverty reduction and healthcare
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by HitGen
HitGen has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Vernalis. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Vernalis is engaged in structure-based drug discovery collaborations.
|
1999 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - HitGen
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Hitgen Comparisons
Competitors of HitGen
HitGen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Omniome, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| domain | founded_year | HQ Location |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| domain | founded_year | HQ Location |
Genome sequencing platform is provided for clinical diagnostics.
|
|
| domain | founded_year | HQ Location |
Dental implants and regenerative dentistry products are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Hitgen
Frequently Asked Questions about HitGen
When was HitGen founded?
HitGen was founded in 2012 and raised its 1st funding round 6 years after it was founded.
Where is HitGen located?
HitGen is headquartered in Lanzhou, China. It is registered at Lanzhou, Gansu, China.
Who is the current CEO of HitGen?
Jin Li is the current CEO of HitGen.
Is HitGen a funded company?
HitGen is a funded company, having raised a total of $39.11M across 2 funding rounds to date. The company's 1st funding round was a Series B of $39.11M, raised on May 28, 2018.
How many employees does HitGen have?
As of Dec 31, 2024, the latest employee count at HitGen is 483.
What is the annual revenue of HitGen?
Annual revenue of HitGen is $58.19M as on Dec 31, 2024.
What does HitGen do?
HitGen Inc. is involved in drug discovery research, focusing on the development of novel medicines and agrochemicals. The company is headquartered in Chengdu, China, with operations in the UK and USA. Advanced technology platforms such as DNA-encoded library (DEL), fragment-based drug discovery (FBDDSBDD), oligonucleotide-based therapeutics (OBT), and targeted protein degradation (TPD) are utilized. Collaboration with numerous biopharmaceutical organizations worldwide is maintained, supporting projects from early discovery to clinical trials. A DELAIAutomated DMTA platform is being developed to enhance preclinical candidate optimization. Diverse sectors including healthcare and agriculture are served through flexible business models.
Who are the top competitors of HitGen?
HitGen's top competitors include Sutro Biopharma, Avidity Biosciences and Antheia.
What products or services does HitGen offer?
HitGen offers DNA Encoded Library (DEL), Fragment-Based Drug Discovery (FBDD/SBDD), Oligonucleotide-Based Therapeutics (OBT), and Targeted Protein Degradation (TPD).
Is HitGen publicly traded?
Yes, HitGen is publicly traded on SSE under the ticker symbol 688222.
How many acquisitions has HitGen made?
HitGen has made 1 acquisition, including Vernalis.
Who are HitGen's investors?
HitGen has 3 investors. Key investors include Gates Foundation, CDH, and Shiyu Capital.
What is HitGen's ticker symbol?
The ticker symbol of HitGen is 688222 on SSE.